title: Strategies for purging CD96+stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.
abstract: The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologous hematopoietic progenitor cell transplantation.
authors.affiliation: Division of Stem Cell Transplantation and Immunotherapy; 2nd Department of Medicine; Christian-Albrechts-University of Kiel; Kiel, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Staudinger
authors.forename: Andreas
authors.initials: A
authors.lastname: Humpe
authors.forename: Martin
authors.initials: M
authors.lastname: Gramatzki
keywords: CD96; acute myeloid leukemia; graft engineering; leukemic stem cells; purging; targeted therapy
references.citation: J Immunol. 2004 Apr 1;172(7):3994-8
references.pmid: 15034010
references.citation: Leukemia. 2007 Jan;21(1):129-35
references.pmid: 17128198
references.citation: Curr Opin Immunol. 2007 Apr;19(2):239-45
references.pmid: 17291742
references.citation: PLoS One. 2012;7(8):e42426
references.pmid: 22879978
references.citation: Blood. 2003 Apr 15;101(8):3142-9
references.pmid: 12468427
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
references.pmid: 17576927
references.citation: Oncogene. 2011 Mar 3;30(9):1009-19
references.pmid: 21076471
references.citation: Exp Hematol. 1998 Dec;26(13):1209-14
references.pmid: 9845376
references.citation: Ann N Y Acad Sci. 1994 May 31;716:204-14; discussion 214-5, 225-7
references.pmid: 8024195
references.citation: Nat Med. 1997 Jul;3(7):730-7
references.pmid: 9212098